| Smarter Analyst | What's Really Driving Interpace Diagnostics Group Inc (NASDAQ:IDXG) The Oracle Dispatch The Company currently has three commercialized molecular tests: PancraGEN, for the evaluation of pancreatic cysts and assessment of risk of concomitant or subsequent cancer; ThyGenX, for the diagnosis of thyroid cancer from thyroid nodules utilizing a ... Maxim Initiates Buy on Diagnostics Group Inc (IDXG); Sees 410% Upside for the StockSmarter Analyst Maxim Group Says Its Time To "Buy" Interpace Diagnostics Gr (IDXG). Will Stock Hit Their Target of $5?WeeklyHub all 80 news articles » |
from # All Medicine by Alexandros G. Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2v2SXtS
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου
Medicine by Alexandros G. Sfakianakis,Anapafseos 5 Agios Nikolaos 72100 Crete Greece,00302841026182,00306932607174,alsfakia@gmail.com,